VirXcel – Innovative treatments against respiratory viral infections based on a novel mode of action.

About Us

Our mission is to develop innovative strategies to prevent and mitigate respiratory
viral infections by leveraging the unique properties of macrocyclic peptides. At
VirXcel, we build on research from Utrecht University, where scientists discovered a
novel macrocyclic peptide that targets a conserved site in the SARS-CoV-2 spike
protein. This region, inaccessible to antibodies, offers a unique therapeutic target
and introduces a new mode of action.

Our company’s first project is focused on delivering a compelling proof-of-concept
data package for an intranasally delivered macrocyclic peptide designed to provide
protection both before and shortly after exposure to SARS-CoV-2.

While vaccines have been critical in controlling the pandemic, the ongoing evolution
of SARS-CoV-2 has ushered in an endemic phase, marked by recurring global
outbreaks. High-risk groups, such as immunocompromised individuals and the
elderly, continue to face elevated risks of severe illness and mortality, despite
widespread vaccination.

Our innovative peptide is designed to offer rapid, targeted protection and early
intervention for these vulnerable populations. Delivered through convenient
intranasal spray technology, it represents a promising new tool to help mitigate
ongoing health threats by preventing infection or reducing the impact of early-stage
viral exposure.

This project not only addresses an urgent clinical need but also showcases the
broader potential of our macrocyclic peptide platform for developing next-generation
interventions against respiratory pathogens.

Technology

Macrocyclic peptides (MCPs) are an emerging class of therapeutic agents distinguished by their compact size, significantly smaller than that of antibodies. This unique property enables them to access and bind to hidden pockets on viral glycoproteins that are often inaccessible to larger molecules, potentially reducing the risk of diminished activity due to viral mutations that typically affect antibody binding.

The pharmaceutical development of MCPs is still at an early stage. To date, only three MCP-based therapies have been launched globally, with several more in clinical development, primarily targeting oncology and cardiovascular diseases.

At VirXcel, we are pioneering the application of macrocyclic peptides for antiviral prevention and early intervention, aiming to unlock their full potential against respiratory and emerging viral threats.